Trials / Completed
CompletedNCT03746860
N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
Non-interventional Study on the Safety and Use of Allergy Immunotherapy ACARIZAX® 12 SQ-HDM in Real-life Clinical Practice in Adult Patients With House Dust Mite Allergy in France
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,508 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (\>18 years) with house dust mite allergy over a period of 12 months.
Detailed description
Condition: * persistent moderate to severe HDM allergic rhinitis despite use of symptom-relieving medication * HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment.
Conditions
- Allergic Rhinitis Due to House Dust Mite
- Allergic Asthma Due to Dermatophagoides Farinae
- Allergic Asthma Due to Dermatophagoides Pteronyssinus
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tablet, Dispersible | 1 tablet/day with 12 SQ-HDM per lyo-tablet |
Timeline
- Start date
- 2018-05-09
- Primary completion
- 2020-09-29
- Completion
- 2020-09-29
- First posted
- 2018-11-20
- Last updated
- 2021-05-17
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03746860. Inclusion in this directory is not an endorsement.